−1.08USD
−52.37 MUSD
43.66 M
About Acumen Pharmaceuticals, Inc.
Sector
CEO
Daniel J. O'Connell
Headquarters
Charlottesville
Website
Employees (FY)
52
Founded
1996
FIGI
BBG0058YJ317
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
$ABOS Long +16% chancebased on simple trend and volume as well as KDJ indicator,i see a good chance for further upside, Next resistance +16% above current price ($4.07 -> $4.9)
ABOS - Long SetupFallen Angel. Insider buying last year. Mostly Big derivative/options action. Looking for a break above 5.67, Stop signal 4.93. Target 8.43. 2nd target 16.83
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ABOS is 3.18 USD — it has increased by 0.63% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Acumen Pharmaceuticals, Inc. stocks are traded under the ticker ABOS.
Acumen Pharmaceuticals, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
ABOS stock is 3.38% volatile and has beta coefficient of 2.37. Check out the list of the most volatile stocks — is Acumen Pharmaceuticals, Inc. there?
ABOS earnings for the last quarter are −0.24 USD per share, whereas the estimation was −0.26 USD resulting in a 8.64% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about Acumen Pharmaceuticals, Inc. earnings.
Yes, you can track Acumen Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
ABOS stock has fallen by 9.14% compared to the previous week, the month change is a 26.05% fall, over the last year Acumen Pharmaceuticals, Inc. has showed a 14.75% decrease.
ABOS net income for the last quarter is −16.50 M USD, while the quarter before that showed −12.96 M USD of net income which accounts for −27.32% change. Track more Acumen Pharmaceuticals, Inc. financial stats to get the full picture.
Today Acumen Pharmaceuticals, Inc. has the market capitalization of 191.05 M, it has decreased by 10.57% over the last week.
No, ABOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ABOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Acumen Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 52.00 employees. See our rating of the largest employees — is Acumen Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Acumen Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Acumen Pharmaceuticals, Inc. stock shows the sell signal. See more of Acumen Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Acumen Pharmaceuticals, Inc. future price: according to them, ABOS price has a max estimate of 15.00 USD and a min estimate of 10.00 USD. Read a more detailed Acumen Pharmaceuticals, Inc. forecast: see what analysts think of Acumen Pharmaceuticals, Inc. and suggest that you do with its stocks.